Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
There are 12,500 GBM patients annually in the US (and 10,000 deaths) and the UK has 2,500 patients. if this therapy works its not unreasonable to expect a price of $80 - 100k per patient A big "if" perhaps but possible... about $5 per share would be cheap given the numbers can probably be multiplied by 2 or 3 worldwide, a buyout or exclusive licence at around £3-£5 a share? Based on 200m shares possibly more? But it has to work...
Just for accuracy, according to Google, Moderna is down 29% Scancell 26 % on the month. Make of that what you will. We know some(one) has been dumping shares here over the last few days,seems like lots of someones have been selling their Moderna stocks. Equally scancell is down 7% on the week , Moderna 14%.
Building blocks and steps up the ladder.. today is confirmation that all is well and moving in the right direction. The news today was never going to be the blockbuster announcement, its too early, but it eases investor worries and frustrations and gives us a road map of sorts. More people will be involved in trials, dosages will change with experience and there is a
tangible excitement in the clinics. Today is a good day
There is a huge gulf between people who jumped in here because of the word Covid and those that have been here for years because of the growing potential of a range of potential cures. Equally anyone reading this mornings RNS without the background understanding would probably shrug their shoulders and move on looking for something that made more sense. Not continuing a covid vax is easy to understand but the apparent success of underpinning technology which might be huge news in the longer term would need to be spelt out much more clearly for the uninitiated. Consequently the SP has improved a little today but the huge market reaction didnt happen, I doubt many LTHs expected it too, but as a building block, today's news may well prove to have been an important milestone.
I thought that the Chairman appointment would be indicative of the direction of future travel, thankfully they have gone for a top business leader, a deal-maker, capable of generating the excitement in the industry for Scancell's products that long- term holders here have always believed were possible. Clearly he knows what we have and is excited, scancell have tweeted this morning that they are excited at his arrival. Excited is the word of the day!
As one of the critics of the commercial side of the business, I warmly welcome this appointment, clearly our new Chairman has the contacts, experience and commercial nous we so urgently needed. Well done to everyone involved in this appointment. It would seem we have caught a whale, a genuine rainmaker who can drive the company to the commercial success its products deserve. Now I am really excited!
Ruck, there is no need to be rude. I have had a colourful and fascinating career. I was challenged to prove what I know about sales and the only " proof" as such is my long and eventful CV littered with great companies and great deals. If you choose to belittle my expertise I guess thats up to you but it makes you a lesser person than I imagined . It is a cheap shot and and unwarranted. I' m sorry you don't value an opinion that differs from the hymn sheet. Lets see who they appoint as the new Chair eh?
Hi Krafty, I have been a salesman most of my working life, I have sold German text books to Ghadaffi, spent time in N. Cyprus dealing with Asil Nadir, I was the first UK salesman to get UK software licenced and translated into Mandarin in China ( at Fudan University), i did multi-million dollar licencing deals with Virgin Interactive, Corel , Interactive Arts and many more in the US. Initially worked for Procter and Gamble and then the Thomson Corporation as UK sales manager for one of their publishing houses before going into international sales in the Software and video games industry.
I think I know a little bit about sales and salesmen. Put simply , great products deserve great deals, underselling is easy, any one can do it.
Cleaner, bearing all that in mind, its a shame we only got £6m upfront from Genmab. It seems like a failure of salesmanship. One of the biggest failings of UK business is to understand the value of what they are selling and an inability on the part of people doing the selling to ask for proper value for their products. Goodfellow was mates with the Genmab crowd, did he do us a favour or did he do them a favour? What number did he put on the table as a starting point ? £600m looks like a decent deal, but its 99% jam tomorrow.I bet he asked for £10m and accepted £6m but where would he have ended up if he had asked ror £100m? Genmab obviously did their due diligence and liked what they saw or there would be no deal at all.
I just wish we had a salesman or woman in the business, my fingers are crossed they find a dealmaker as the new Chairman or woman, someone who knows the value of what he is selling and has the minerals to ask for a big number.
Tweet
See new Tweets
Conversation
Scancell
@scancellpharma
We are pleased to have been awarded a Singaporean patent on our anti-glycan monoclonal antibody with specificity for the sialyl-di-Lewis? glycan expressed on glycoprotein
Chester, it feels as though they are clearing the decks....get the interims out of the way and then have a clear runway for other ( good) news. Better than making a big announcement and then having the interims and then trying to get back to the good news I would have thought, especially if the good news makes the interims somewhat redundant.
I am reminded that when we were all excited about the SCIB1 trial results, many said that there were not enough people in the trial to warrant any big offers being made. Clearly there are more in the MODI 1 trial, but I wonder if Lindy has SCIB1 in the back of mind and is waiting for a ton of irrefutable data prior to writing the killer RNS. They know it seems to be working, we know its working for at least one person, at some point we hope Lindy will be able to "blow the bloody doors off" but to do that, she has to collect lots of data and the numbers involved will need to be enough to prevent the naysayers from talking it down. Meanwhile we wait.... Tick Tock
Just found the FDA approved list of Mabs with companies that own them
https://en.wikipedia.org/wiki/Monoclonal_antibody_therapy
Konar, thanks , I kind of figured that the Mab bit was indicative, I was being lazy! I found a wiki entry on mabs and it would seem there arr over 500 of them listed! I have no idea how many are actually in use but its a lot more than I imagined. And if they can benefit from Avidimab ... multi multi multi millions!
https://en.wikipedia.org/wiki/List_of_therapeutic_monoclonal_antibodies
Konar...."but there are plenty of companies out there that will happily mass produce generic versions of off patent medication and undercut the market."
Have I misunderstood this, or does this infer that Scancell or a company licencing avidimab, could take lots of existing, out of patent, medicines and add avidimab to them to create a new patented, and more effective version of the current product? This would be potentially a huge licencing opportunity, does anyone have any idea how many drugs are out there that could benefit?
From wiki
In December 2022, Merck announced a licensing deal with Kelun-Biotech of China whereby it would expand it's early cancer pipeline with a set of antibody-drug conjugates; this follows an earlier agreement between the two companies to co-develop such drugs
“I can’t really believe that result yet;... It has completely blown my socks off that the vaccine should be working so well, so early in the process. Once we get more results from other parts of the trial we will issue an absolutely stonking RNS"
“I can’t really believe that result yet;... It has completely blown my socks off that the vaccine should be working so well, so early in the process. Once we get more results from other parts of the trial we will issue an absolutely stonking RNS"
I think HMG may be keen to be seen to be doing "something" to mitigate the disaster of 2 years of the NHS being practically closed to 1000s of new cancer patients. The new BioNtech collaboration is not expected to bear fruit until 2030 so imagine their excitement if Lindy has pulled their tripes out of the mincer! They will be all over us like a rash.